Recent Developments in Studies on the Relation Between Endometriosis and Ovarian Cancer: Phenotype-Specific Risk, Molecular Convergence and Clinical Risk Stratification

Review OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-10 ⓘ

This narrative review synthesizes recent evidence linking endometriosis phenotypes, particularly clear-cell and endometrioid ovarian carcinoma, to molecular alterations while recommending individualized risk assessment over routine surveillance due to low absolute incidence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background/Objectives: We aim to synthesize recent clinical and translational evidence on the relationship between endometriosis and ovarian cancer, with emphasis on publications from 2024 to 2026 and on clinically conservative risk stratification. Materials and Methods: This state-of-the-art narrative review prioritizes major peer-reviewed publications from July 2024 to June 2026. Older landmark publications were used only where necessary to contextualize recent findings. Results: Recent evidence supports a selective, phenotype-dependent association instead of a generalized malignant potential of endometriosis. The strongest and most reproducible signal concerns epithelial ovarian cancer, especially clear-cell and endometrioid ovarian carcinoma, with the highest relative risks reported for ovarian endometrioma and/or deep endometriosis. The ENDOCANCER meta-analysis found increased ovarian cancer risk across odds ratio, hazard ratio and standardized incidence ratio estimates but confirmed low absolute incidence and substantial heterogeneity. Contemporary reviews, including Leone Roberti Maggiore et al. and Bogani et al., emphasize low absolute lifetime risk and the absence of evidence supporting universal oncologic surveillance. Newer clinicopathological studies distinguish endometriosis-correlated tumors supported by transitional lesions indicative of malignant transformation from incidental coexistence. Molecular data support biological plausibility through ARID1A, PIK3CA, KRAS, PTEN, mismatch repair deficiency, POLE-mutated disease and p53-abnormal phenotypes, but these markers are not ready for routine prediction in endometriosis care. Conclusions: The immediate clinical implication is individualized risk assessment in place of routine cancer screening or prophylactic surgery based solely on the increased cancer risk associated with endometriosis. Counseling should integrate endometriosis phenotype, age, menopausal status, lesion dynamics, imaging atypia, hereditary cancer risk, reproductive goals and surgical consequences.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

SciLite annotations

chemicals 15
estrogen heme iron platinum platinum platinum iron estrogen progesterone oxygen iron iron platinum deoxyribonucleic acid oxygen
organisms 4
mus sp. multicellular animals human mus sp.

Source provenance

europepmc
last seen: 2026-11-22T09:57:54.571072+00:00
openalex
last seen: 2026-11-22T06:06:27.128750+00:00
pubmed
last seen: 2026-11-22T06:08:19.120011+00:00
scilite
last seen: 2026-10-25T10:06:56.708568+00:00
License: CC0 · commercial use OK